Literature DB >> 20198540

[Systemic manifestations and comorbidities in patients with chronic obstructive pulmonary disease (COPD) and their effect on clinical state and course of the disease--an overview of the cohort study COSYCONET].

R A Jörres1, T Welte, R Bals, A Koch, M Schnoor, C Vogelmeier.   

Abstract

BACKGROUND AND RATIONALE: The integrated project COSYCONET, as part of the competence network ASCONET funded by the BMBF, has the aim to investigate the relationship between the pulmonary disorder, comorbidities and systemic inflammation in patients with chronic obstructive pulmonary disease (COPD) by adopting cross-sectional as well as longitudinal analyses. METHODOLOGICAL APPROACH: COSYCONET includes a number of projects addressing the issue of comorbidities at the basic science level. Its core project, however, is the establishment of a cohort of patients with COPD, which is compared with two population-based control cohorts. The COPD cohort will include 3,000 patients, among them 1,500 with severity according to GOLD category I/II and 1,500 with category III/IV. Patients will be recruited in study centers covering all major regions of Germany, and this will be achieved in close cooperation with pneumologists from private practices. After recruitment, patients will be studied upon an initial visit as well as 6 and 18 months later. Each visit includes a comprehensive battery of functional tests and questionnaires that aim at assessing the state of the disease as accurately and completely as feasible, comprising lung function and the individual pattern and risk factors of comorbidities including cardiovascular disorders, metabolic disorders, osteoporosis, exercise capacity, acticity and mental status. In addition blood samples will be taken and asservated in a biobank in order to assess markers of systemic inflammation and aging as well as organ-specific markers. Moreover morphological information on the lung as available from HR-CT pictures that have not been specifically taken for the study will be analysed semi-quantitatively in a central facility and standardised manner. Georg Thieme Verlag KG Stuttgart , New York.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20198540     DOI: 10.1055/s-0030-1249185

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  13 in total

1.  [Pulmonary diseases in the elderly].

Authors:  M Gogol; H J Heppner
Journal:  Z Gerontol Geriatr       Date:  2011-08       Impact factor: 1.281

2.  [COPD and heart disease].

Authors:  H Watz; M Arzt
Journal:  Herz       Date:  2014-02       Impact factor: 1.443

3.  [Drug therapy in the elderly].

Authors:  M Gogol
Journal:  Z Gerontol Geriatr       Date:  2014-06       Impact factor: 1.281

4.  [Cardiovascular outcome in patients with COPD : Study to Understand Mortality and Morbidity (SUMMIT)].

Authors:  T Welte; S Nitschmann
Journal:  Internist (Berl)       Date:  2016-11       Impact factor: 0.743

5.  Repeatability of and relationship between potential COPD biomarkers in bronchoalveolar lavage, bronchial biopsies, serum, and induced sputum.

Authors:  Stefan Röpcke; Olaf Holz; Gereon Lauer; Meike Müller; Susanne Rittinghausen; Peter Ernst; Gezim Lahu; Martin Elmlinger; Norbert Krug; Jens M Hohlfeld
Journal:  PLoS One       Date:  2012-10-04       Impact factor: 3.240

6.  Assessing health-related quality of life in COPD: comparing generic and disease-specific instruments with focus on comorbidities.

Authors:  Margarethe E Wacker; Rudolf A Jörres; Annika Karch; Sarah Wilke; Joachim Heinrich; Stefan Karrasch; Armin Koch; Holger Schulz; Henrik Watz; Reiner Leidl; Claus Vogelmeier; Rolf Holle
Journal:  BMC Pulm Med       Date:  2016-05-10       Impact factor: 3.317

7.  Relative impact of COPD and comorbidities on generic health-related quality of life: a pooled analysis of the COSYCONET patient cohort and control subjects from the KORA and SHIP studies.

Authors:  Margarethe E Wacker; Rudolf A Jörres; Annika Karch; Armin Koch; Joachim Heinrich; Stefan Karrasch; Holger Schulz; Annette Peters; Sven Gläser; Ralf Ewert; Sebastian E Baumeister; Claus Vogelmeier; Reiner Leidl; Rolf Holle
Journal:  Respir Res       Date:  2016-07-12

8.  Systematic Analysis of Self-Reported Comorbidities in Large Cohort Studies - A Novel Stepwise Approach by Evaluation of Medication.

Authors:  Tanja Lucke; Ronald Herrera; Margarethe Wacker; Rolf Holle; Frank Biertz; Dennis Nowak; Rudolf M Huber; Sandra Söhler; Claus Vogelmeier; Joachim H Ficker; Harald Mückter; Rudolf A Jörres
Journal:  PLoS One       Date:  2016-10-28       Impact factor: 3.240

9.  Transfer factor for carbon monoxide in patients with COPD and diabetes: results from the German COSYCONET cohort.

Authors:  Kathrin Kahnert; Tanja Lucke; Frank Biertz; Andreas Lechner; Henrik Watz; Peter Alter; Robert Bals; Jürgen Behr; Rolf Holle; Rudolf M Huber; Stefan Karrasch; Beate Stubbe; Margarethe Wacker; Sandra Söhler; Emiel F M Wouters; Claus Vogelmeier; Rudolf A Jörres
Journal:  Respir Res       Date:  2017-01-13

10.  Osteoporosis in Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome.

Authors:  Jee Youn Oh; Young Seok Lee; Kyung Hoon Min; Sung Yong Lee; Jae Jeong Shim; Kyung Ho Kang; Gyu Young Hur
Journal:  Tuberc Respir Dis (Seoul)       Date:  2017-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.